RWD277 COST-UTILITY IN DAPAGLIFLOZIN VERSUS SACUBITRIL-VALSARTAN THERAPY IN HEART FAILURE WITH REDUCED EJECTION FRACTION [DESTINY-HF]: A PRAGMATIC RANDOMIZED CONTROLLED TRIAL-BASED ECONOMIC EVALUATION

Résumé fourni par la source

Angiotensin Receptor-Neprilysin Inhibitors (ARNI) and Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i) are first line drugs for heart failure with reduced ejection fraction (HFrEF). There is considerable cost differences between the two class of drugs. But there is uncertain evidence on difference in effectiveness between these two first-line options as there is lack of real world evidence and no head-to-head randomized controlled trials (RCTs) prior to this study. This research aimed to assess the relative cost utility to aid the choice of one drug over the other in HFrEF.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.